{"id":"W1423581981","doi":"10.1016/j.jacl.2015.08.006","title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","year":2015,"lang":"en","type":"article","venue":"Journal of clinical lipidology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":467,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Amarin Corporation; Regeneron Pharmaceuticals; Eli Lilly and Company; AstraZeneca; CSL Behring; Danone; Amarin Pharma; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Esperion Therapeutics; GlaxoSmithKline","keywords":"Medicine; Alirocumab; Ezetimibe; Statin; Internal medicine; Pharmacology; Cholesterol; Total cholesterol","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001309314,0.00134892,0.003454078,0.0003040603,0.000384584,0.001404139,0.0006585781,0.001174253,0.004332014],"category_scores_gemma":[0.001723231,0.0005109783,0.002203168,0.0002675086,0.001134014,0.001158122,0.0007364271,0.002604965,0.0004342365],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007233522,"about_ca_system_score_gemma":0.0006595845,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001298553,"about_ca_topic_score_gemma":0.002707583,"domain_scores_codex":[0.9994001,0.0002974387,0.00004494504,0.0001245002,0.00005024091,0.00008274308],"domain_scores_gemma":[0.9991388,0.0002865149,0.0002154738,0.00008624785,0.00004097392,0.0002319113],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9867418,0.0007799407,0.001792593,0.0004033236,0.00197206,0.00004186251,0.00003812374,0.0001851835,0.001175653,0.0001585718,0.0003190233,0.006391815],"study_design_scores_gemma":[0.9603225,0.02319712,0.01013782,0.00007636449,0.003717578,0.00007947008,0.0000960872,0.0008155048,0.0003170178,0.0005606253,0.0006459211,0.00003400934],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910945,0.005392345,0.0003662232,0.0008240745,0.0002853204,0.0002242417,0.0005331199,0.00002945464,0.001250654],"genre_scores_gemma":[0.9954576,0.001478013,0.0005073963,0.0006655774,0.0002706274,0.0002110463,0.0004542239,0.000008699545,0.0009467864],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004332014,"threshold_uncertainty_score":0.01449198,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0757458802216295,"score_gpt":0.3849540900123038,"score_spread":0.3092082097906743,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}